Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group.
Werner
B G
BG
Massachusetts State Laboratory Institute, Boston 02130.
Snydman
D R
DR
Freeman
R
R
Rohrer
R
R
Tilney
N L
NL
Kirkman
R L
RL
D000328:Adult; D003586:Cytomegalovirus Infections / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D011446:Prospective Studies; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D014019:Tissue Donors; D016896:Treatment Outcome
D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; C045781:cytomegalovirus-specific hyperimmune globulin